SG11201500682WA - Fusion proteins for treating a metabolic syndrome - Google Patents
Fusion proteins for treating a metabolic syndromeInfo
- Publication number
- SG11201500682WA SG11201500682WA SG11201500682WA SG11201500682WA SG11201500682WA SG 11201500682W A SG11201500682W A SG 11201500682WA SG 11201500682W A SG11201500682W A SG 11201500682WA SG 11201500682W A SG11201500682W A SG 11201500682WA SG 11201500682W A SG11201500682W A SG 11201500682WA
- Authority
- SG
- Singapore
- Prior art keywords
- treating
- fusion proteins
- metabolic syndrome
- metabolic
- syndrome
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factors [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12306072 | 2012-09-07 | ||
PCT/EP2013/068239 WO2014037373A1 (en) | 2012-09-07 | 2013-09-04 | Fusion proteins for treating a metabolic syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201500682WA true SG11201500682WA (en) | 2015-02-27 |
Family
ID=46888349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201500682WA SG11201500682WA (en) | 2012-09-07 | 2013-09-04 | Fusion proteins for treating a metabolic syndrome |
Country Status (25)
Country | Link |
---|---|
US (3) | US20140073563A1 (en) |
EP (1) | EP2892919A1 (en) |
JP (1) | JP2015533483A (en) |
KR (1) | KR20150043505A (en) |
CN (1) | CN104736558A (en) |
AR (1) | AR092456A1 (en) |
AU (1) | AU2013311777B2 (en) |
BR (1) | BR112015004734A2 (en) |
CA (1) | CA2880929A1 (en) |
CL (1) | CL2015000379A1 (en) |
CR (1) | CR20150149A (en) |
DO (1) | DOP2015000020A (en) |
EA (1) | EA201590525A1 (en) |
GT (1) | GT201500049A (en) |
HK (1) | HK1207097A1 (en) |
IL (1) | IL237032A0 (en) |
MA (1) | MA37963A1 (en) |
MX (1) | MX2015002985A (en) |
PE (1) | PE20150648A1 (en) |
PH (1) | PH12015500194A1 (en) |
SG (1) | SG11201500682WA (en) |
TN (1) | TN2015000053A1 (en) |
TW (1) | TW201414750A (en) |
UY (1) | UY35018A (en) |
WO (1) | WO2014037373A1 (en) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140012199A (en) | 2007-03-30 | 2014-01-29 | 암브룩스, 인코포레이티드 | Modified fgf-21 polypeptides and their uses |
AU2012279237B2 (en) | 2011-07-01 | 2016-09-29 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
AU2013352363B2 (en) | 2012-11-28 | 2018-04-12 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
CN108888757A (en) | 2012-12-27 | 2018-11-27 | 恩格姆生物制药公司 | Method for adjusting bile acid homeostasis and treating bile acid disorder and disease |
CN105828878A (en) | 2013-10-28 | 2016-08-03 | 恩格姆生物制药公司 | Cancer models and associated methods |
EP3097122B9 (en) | 2014-01-24 | 2020-11-11 | NGM Biopharmaceuticals, Inc. | Antibodies binding beta klotho domain 2 and methods of use thereof |
WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
AU2015277438B2 (en) | 2014-06-16 | 2020-02-27 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
NZ728488A (en) * | 2014-07-29 | 2023-03-31 | Shenzhen Hightide Biopharmaceutical Ltd | Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof |
KR102569907B1 (en) | 2014-10-23 | 2023-08-24 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | Pharmaceutical Compositions Comprising Peptide Variants and Methods of Use Thereof |
TWI705071B (en) | 2014-10-24 | 2020-09-21 | 美商必治妥美雅史谷比公司 | Modified fgf-21 polypeptides and uses thereof |
US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
MY181181A (en) * | 2014-12-23 | 2020-12-21 | Novo Nordisk As | Fgf21 derivatives and uses thereof |
CN105801705B (en) * | 2014-12-31 | 2019-05-24 | 天境生物科技(上海)有限公司 | Fused polypeptide and application thereof containing glucagon-like-peptide-1 and immunoglobulin heterozygosis Fc |
US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
WO2017024182A1 (en) | 2015-08-04 | 2017-02-09 | Duke University | Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same |
KR20170049320A (en) * | 2015-10-28 | 2017-05-10 | 주식회사유한양행 | Dual function proteins and pharmaceutical composition comprising the same |
ES2871036T3 (en) | 2015-11-09 | 2021-10-28 | Ngm Biopharmaceuticals Inc | Method for treating bile acid-related disorders |
US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
MX2018008681A (en) | 2016-01-13 | 2018-09-17 | Novo Nordisk As | Egf(a) analogues with fatty acid substituents. |
US20190192626A1 (en) * | 2016-04-29 | 2019-06-27 | Defensin Therapeutics Aps | Treatment of liver, biliary tract and pancreatic disorders |
WO2017210476A1 (en) | 2016-06-01 | 2017-12-07 | Duke University | Nonfouling biosensors |
US11123438B2 (en) | 2016-08-19 | 2021-09-21 | Ampsource Biopharma Shanghai Inc. | Linker peptide for constructing fusion protein |
CN107759697B (en) | 2016-08-19 | 2023-03-24 | 安源医药科技(上海)有限公司 | Method for producing fusion protein |
CN106279437B (en) | 2016-08-19 | 2017-10-31 | 安源医药科技(上海)有限公司 | Hyperglycosylated human coagulation factor VIII fusion proteins and preparation method thereof and purposes |
WO2018039557A1 (en) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
EP3558341A1 (en) * | 2016-12-22 | 2019-10-30 | Sanofi | Fgf21 compound / glp-1r agonist combinations with optimized activity ratio |
WO2018132732A1 (en) | 2017-01-12 | 2018-07-19 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
CN108440668A (en) * | 2017-02-16 | 2018-08-24 | 瑞阳(苏州)生物科技有限公司 | The fusion protein of FGF21 and IGF-1 and its application |
CN108570109B (en) * | 2017-03-14 | 2022-04-26 | 广东东阳光药业有限公司 | Dual target fusion proteins comprising an immunoglobulin Fc portion |
JP7191850B2 (en) | 2017-04-21 | 2022-12-19 | ユーハン・コーポレイション | Methods for Producing Dual-Functional Proteins and Derivatives Thereof |
US11554097B2 (en) | 2017-05-15 | 2023-01-17 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
EP3658168A4 (en) | 2017-06-30 | 2021-07-14 | Duke University | Order and disorder as a design principle for stimuli-responsive biopolymer networks |
JP7339236B2 (en) | 2017-07-19 | 2023-09-05 | ノヴォ ノルディスク アー/エス | Bifunctional compound |
SG11202001637PA (en) | 2017-09-22 | 2020-03-30 | Regeneron Pharma | Glucagon-like peptide 1 receptor agonists and uses thereof |
DK3707261T3 (en) * | 2017-11-06 | 2022-07-11 | Thena Biotech S R L | Fusion proteins based on human ferritin and protease-cleavable peptides and their use as chemotherapy carriers |
CN115109166A (en) * | 2017-11-24 | 2022-09-27 | 浙江道尔生物科技有限公司 | Multi-domain active protein for treating metabolic diseases |
CN109929806B (en) | 2017-12-19 | 2020-05-08 | 北京吉源生物科技有限公司 | Stem cell expressing GLP1 and FGF21 and application thereof |
CN110028587B (en) * | 2018-01-11 | 2021-10-08 | 安源医药科技(上海)有限公司 | Synergistic bifunctional proteins for regulating blood glucose and lipids |
CN116098989A (en) * | 2018-02-08 | 2023-05-12 | 广东东阳光药业有限公司 | FGF21 variants, fusion proteins and uses thereof |
WO2019243557A1 (en) | 2018-06-21 | 2019-12-26 | Sanofi | Fgf21 compound / glp-1r agonist combinations with optimized activity ratio |
US11649275B2 (en) | 2018-08-02 | 2023-05-16 | Duke University | Dual agonist fusion proteins |
CN109836486B (en) * | 2019-01-30 | 2020-09-08 | 北京双因生物科技有限公司 | Fibroblast growth factor 21 variants, fusion proteins thereof, and uses thereof |
CN111944055B (en) * | 2019-05-16 | 2022-08-02 | 浙江道尔生物科技有限公司 | Fusion protein for treating metabolic diseases |
US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
CN116925237A (en) | 2019-12-31 | 2023-10-24 | 北京质肽生物医药科技有限公司 | Fusion proteins of GLP-1 and GDF15 and conjugates thereof |
CN115322794A (en) | 2020-01-11 | 2022-11-11 | 北京质肽生物医药科技有限公司 | Conjugates of fusion proteins of GLP-1 and FGF21 |
CN113735977A (en) * | 2020-05-28 | 2021-12-03 | 江苏康缘瑞翱生物医药科技有限公司 | rhFGF21 fusion protein, polynucleotide for coding same, composition containing same and application thereof |
US20220010021A1 (en) | 2020-07-02 | 2022-01-13 | Sanofi | FGFR1/KLB Targeting Agonistic Antigen-Binding Proteins and Conjugates Thereof with GLP-1R Agonistic Peptides |
WO2022010319A1 (en) * | 2020-07-10 | 2022-01-13 | (주)지아이이노베이션 | Fusion protein including glucagon-like peptide-1 and interleukin-1 receptor antagonist and use thereof |
WO2022117044A1 (en) * | 2020-12-03 | 2022-06-09 | Sunshine Lake Pharma Co., Ltd. | Glp-1/gcg dual receptor agonist polypeptide and fusion protein thereof |
AR125086A1 (en) * | 2021-03-23 | 2023-06-07 | Lilly Co Eli | COMPOSITIONS CONTAINING INCRETIN ANALOGUES AND USES THEREOF |
CN113150172B (en) * | 2021-04-28 | 2023-09-22 | 中国药科大学 | GLP-1R/GIPR double-target agonist fusion protein and preparation method and application thereof |
WO2022256568A1 (en) * | 2021-06-02 | 2022-12-08 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for localization of growth factors |
WO2023284822A1 (en) * | 2021-07-14 | 2023-01-19 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion polypeptides for metabolic disorders |
CN113583142A (en) * | 2021-08-20 | 2021-11-02 | 赣江中药创新中心 | Double-target fusion protein, coding gene, vector or host cell and application and expression and purification method thereof |
WO2023049631A2 (en) * | 2021-09-09 | 2023-03-30 | Northwestern University | Cell-free methods and compositions comprising tagless therapeutic hormones |
WO2024064842A1 (en) | 2022-09-21 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03219892A (en) * | 1990-01-24 | 1991-09-27 | Kyowa Hakko Kogyo Co Ltd | Method for preparing protein |
GB9725556D0 (en) * | 1997-12-03 | 1998-02-04 | Ciba Geigy Ag | Organic compounds |
MXPA01006922A (en) * | 1999-01-07 | 2002-04-24 | Lexigen Pharm Corp | EXPRESSION AND EXPORT OF ANTI-OBESITY PROTEINS AS Fc FUSION PROTEINS. |
US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7138370B2 (en) * | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
CN1480466A (en) * | 2002-09-03 | 2004-03-10 | �й������ž�����ҽѧ��ѧԺ����ҽ | Interfusion protein possessing dual functions of thrombolysis and anticoagulation as well as its application |
EA012082B1 (en) * | 2004-08-03 | 2009-08-28 | Транстек Фарма, Инк. | Rage fusion proteins and methods of use |
WO2007005604A2 (en) * | 2005-07-05 | 2007-01-11 | The Regents Of The University Of California | Polynucleotides encoding isoprenoid modifying enzymes and methods of use thereof |
US7625564B2 (en) * | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
PE20081140A1 (en) * | 2006-10-25 | 2008-09-22 | Amgen Inc | THERAPEUTIC AGENTS BASED ON PEPTIDES DERIVED FROM TOXINS |
WO2009020802A2 (en) * | 2007-08-03 | 2009-02-12 | Eli Lilly And Company | Treatment for obesity |
JP2010536341A (en) * | 2007-08-15 | 2010-12-02 | アムニクス, インコーポレイテッド | Compositions and methods for altering properties of biologically active polypeptides |
MX2011008094A (en) * | 2009-02-03 | 2012-02-13 | Amunix Operating Inc | Extended recombinant polypeptides and compositions comprising same. |
CN101993485B (en) * | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | Peptide analog homologous dimer capable of accelerating insulin secretion and application thereof |
EP2488199A1 (en) * | 2009-10-14 | 2012-08-22 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
US20110312881A1 (en) * | 2009-12-21 | 2011-12-22 | Amunix, Inc. | Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases |
EP2460527A1 (en) * | 2010-01-21 | 2012-06-06 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
AU2011350066A1 (en) * | 2010-12-27 | 2013-07-11 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
US9458214B2 (en) * | 2011-09-26 | 2016-10-04 | Novartis Ag | Dual function fibroblast growth factor 21 proteins |
US9676857B2 (en) * | 2012-03-16 | 2017-06-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Soluble engineered monomeric Fc |
-
2013
- 2013-09-04 CN CN201380046749.3A patent/CN104736558A/en active Pending
- 2013-09-04 MA MA37963A patent/MA37963A1/en unknown
- 2013-09-04 MX MX2015002985A patent/MX2015002985A/en unknown
- 2013-09-04 JP JP2015530371A patent/JP2015533483A/en active Pending
- 2013-09-04 PE PE2015000288A patent/PE20150648A1/en not_active Application Discontinuation
- 2013-09-04 KR KR1020157007317A patent/KR20150043505A/en not_active Application Discontinuation
- 2013-09-04 AU AU2013311777A patent/AU2013311777B2/en not_active Ceased
- 2013-09-04 SG SG11201500682WA patent/SG11201500682WA/en unknown
- 2013-09-04 EA EA201590525A patent/EA201590525A1/en unknown
- 2013-09-04 BR BR112015004734A patent/BR112015004734A2/en not_active IP Right Cessation
- 2013-09-04 EP EP13758851.3A patent/EP2892919A1/en not_active Withdrawn
- 2013-09-04 CA CA2880929A patent/CA2880929A1/en not_active Abandoned
- 2013-09-04 WO PCT/EP2013/068239 patent/WO2014037373A1/en active Application Filing
- 2013-09-05 AR ARP130103163A patent/AR092456A1/en unknown
- 2013-09-06 US US14/019,735 patent/US20140073563A1/en not_active Abandoned
- 2013-09-06 TW TW102132110A patent/TW201414750A/en unknown
- 2013-09-06 UY UY0001035018A patent/UY35018A/en not_active Application Discontinuation
-
2015
- 2015-01-29 PH PH12015500194A patent/PH12015500194A1/en unknown
- 2015-02-01 IL IL237032A patent/IL237032A0/en unknown
- 2015-02-05 DO DO2015000020A patent/DOP2015000020A/en unknown
- 2015-02-17 CL CL2015000379A patent/CL2015000379A1/en unknown
- 2015-02-18 TN TNP2015000053A patent/TN2015000053A1/en unknown
- 2015-02-27 GT GT201500049A patent/GT201500049A/en unknown
- 2015-03-19 CR CR20150149A patent/CR20150149A/en unknown
- 2015-08-13 HK HK15107811.5A patent/HK1207097A1/en unknown
- 2015-12-10 US US14/965,841 patent/US20160194371A1/en not_active Abandoned
-
2018
- 2018-07-27 US US16/047,695 patent/US20190085043A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TN2015000053A1 (en) | 2016-06-29 |
JP2015533483A (en) | 2015-11-26 |
GT201500049A (en) | 2016-02-15 |
KR20150043505A (en) | 2015-04-22 |
UY35018A (en) | 2014-03-31 |
CA2880929A1 (en) | 2014-03-13 |
HK1207097A1 (en) | 2016-01-22 |
CL2015000379A1 (en) | 2015-06-05 |
WO2014037373A1 (en) | 2014-03-13 |
AU2013311777B2 (en) | 2018-02-01 |
MA37963A1 (en) | 2018-06-29 |
US20140073563A1 (en) | 2014-03-13 |
BR112015004734A2 (en) | 2017-11-21 |
CR20150149A (en) | 2015-05-29 |
US20160194371A1 (en) | 2016-07-07 |
PH12015500194A1 (en) | 2015-04-20 |
AR092456A1 (en) | 2015-04-22 |
DOP2015000020A (en) | 2015-04-15 |
PE20150648A1 (en) | 2015-05-25 |
CN104736558A (en) | 2015-06-24 |
EP2892919A1 (en) | 2015-07-15 |
MX2015002985A (en) | 2015-06-22 |
US20190085043A1 (en) | 2019-03-21 |
TW201414750A (en) | 2014-04-16 |
IL237032A0 (en) | 2015-03-31 |
AU2013311777A1 (en) | 2015-03-19 |
EA201590525A1 (en) | 2015-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1207097A1 (en) | Fusion proteins for treating a metabolic syndrome | |
HRP20181558T1 (en) | Fusion proteins for treating metabolic disorders | |
HK1197201A1 (en) | Autoinjector | |
HK1192587A1 (en) | Therapeutic fusion proteins | |
GB2583417B (en) | A protein | |
HK1198581A1 (en) | Autoinjector | |
IL229258A0 (en) | Polypeptides | |
IL232694A0 (en) | Autoinjector | |
EP2738583A4 (en) | Fusion splicer | |
IL232124A0 (en) | Autoinjector | |
EP2683742A4 (en) | Npp1 fusion proteins | |
EP2698386A4 (en) | Fusion protein | |
EP2713442A4 (en) | Rotman lens | |
EP2829603A4 (en) | Protein alignment method | |
AU4710P (en) | Fusion xTriticosecale | |
GB201114701D0 (en) | Fusion proteins | |
GB201107189D0 (en) | Fusion proteins | |
GB201104152D0 (en) | Fusion Polypeptide | |
GB201204065D0 (en) | Fusion polypeptide | |
GB201112985D0 (en) | Polypeptide | |
GB201112849D0 (en) | Polypeptide | |
GB201106130D0 (en) | Polypeptide | |
HUE047406T2 (en) | Polypeptides |